Dusan Stefoski

4.5k total citations
56 papers, 2.7k citations indexed

About

Dusan Stefoski is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Dusan Stefoski has authored 56 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pathology and Forensic Medicine, 20 papers in Oncology and 12 papers in Immunology. Recurrent topics in Dusan Stefoski's work include Multiple Sclerosis Research Studies (32 papers), Polyomavirus and related diseases (12 papers) and Peripheral Neuropathies and Disorders (8 papers). Dusan Stefoski is often cited by papers focused on Multiple Sclerosis Research Studies (32 papers), Polyomavirus and related diseases (12 papers) and Peripheral Neuropathies and Disorders (8 papers). Dusan Stefoski collaborates with scholars based in United States, United Kingdom and Germany. Dusan Stefoski's co-authors include Floyd A. Davis, Eva Havrdová, Gavin Giovannoni, Steven Galetta, Anthony T. Reder, Stephen Lloyd, C. L. Schauf, Richard K. Burt, Bruce A. Cohen and Jacob Elkins and has published in prestigious journals such as The Lancet, Journal of Neuroscience and Blood.

In The Last Decade

Dusan Stefoski

52 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dusan Stefoski United States 24 1.7k 641 592 543 456 56 2.7k
Philippe Truffinet France 18 2.0k 1.2× 946 1.5× 636 1.1× 407 0.7× 622 1.4× 68 2.6k
Vesna Brinar Croatia 22 2.6k 1.5× 1.2k 1.9× 600 1.0× 576 1.1× 781 1.7× 99 3.5k
Norman Putzki Switzerland 25 1.6k 0.9× 668 1.0× 390 0.7× 351 0.6× 293 0.6× 48 2.1k
Luca Massacesi Italy 33 1.7k 1.0× 648 1.0× 489 0.8× 955 1.8× 552 1.2× 123 3.3k
Mefkûre Eraksoy Türkiye 28 1.2k 0.7× 810 1.3× 254 0.4× 405 0.7× 398 0.9× 97 2.4k
Daniel Wynn United States 26 2.7k 1.6× 1.1k 1.8× 1.0k 1.7× 792 1.5× 653 1.4× 50 3.6k
Catherine M. Dalton United Kingdom 20 1.7k 1.0× 739 1.2× 484 0.8× 463 0.9× 586 1.3× 37 2.6k
J. A. Cohen United States 13 2.5k 1.4× 1.2k 1.8× 523 0.9× 591 1.1× 792 1.7× 23 3.0k
Clas Malmeström Sweden 28 2.0k 1.2× 991 1.5× 641 1.1× 589 1.1× 463 1.0× 67 3.1k
Marc Debouverie France 27 2.1k 1.3× 885 1.4× 385 0.7× 230 0.4× 559 1.2× 89 2.7k

Countries citing papers authored by Dusan Stefoski

Since Specialization
Citations

This map shows the geographic impact of Dusan Stefoski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dusan Stefoski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dusan Stefoski more than expected).

Fields of papers citing papers by Dusan Stefoski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dusan Stefoski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dusan Stefoski. The network helps show where Dusan Stefoski may publish in the future.

Co-authorship network of co-authors of Dusan Stefoski

This figure shows the co-authorship network connecting the top 25 collaborators of Dusan Stefoski. A scholar is included among the top collaborators of Dusan Stefoski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dusan Stefoski. Dusan Stefoski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Giovannoni, Gavin, Alexey Boyко, Jorge Correale, et al.. (2023). Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Multiple Sclerosis Journal. 29(6). 719–730. 23 indexed citations
2.
Stefoski, Dusan, et al.. (2023). Cyclophosphamide for severe acute forms of central nervous system inflammatory disorders. Journal of the Neurological Sciences. 451. 120693–120693. 4 indexed citations
3.
Gold, Ralf, Ernst‐Wilhelm Radue, Gavin Giovannoni, et al.. (2020). Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. Journal of Neurology. 267(10). 2851–2864. 8 indexed citations
4.
Gold, Ralf, Ernst‐Wilhelm Radue, Gavin Giovannoni, et al.. (2016). Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurology. 16(1). 117–117. 39 indexed citations
5.
Gold, Ralf, Dusan Stefoski, Krzysztof Selmaj, et al.. (2016). Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program. Neurology and Therapy. 5(2). 169–182. 13 indexed citations
6.
Radue, Ernst‐Wilhelm, Dusan Stefoski, Ralf Gold, et al.. (2014). Reduction in Brain Atrophy with Extended Daclizumab HYP Treatment: Results of SELECT and the SELECT Extension Study (P3.187). Neurology. 82(10_supplement). 2 indexed citations
7.
Tan, Lee A., et al.. (2014). Is cervical decompression beneficial in patients with coexistent cervical stenosis and multiple sclerosis?. Journal of Clinical Neuroscience. 21(12). 2189–2193. 8 indexed citations
8.
9.
10.
Giovannoni, Gavin, Ralf Gold, Krzysztof Selmaj, et al.. (2013). The Safety and Efficacy of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis in the SELECTION Extension Study: Primary Results (S01.001). Neurology. 80(7_supplement). 3 indexed citations
11.
Ren, Zhihua, Yan Wang, Thomas Liggett, et al.. (2011). IRF-1 signaling in central nervous system glial cells regulates inflammatory demyelination. Journal of Neuroimmunology. 233(1-2). 147–159. 23 indexed citations
12.
Ren, Zhiyong Jason, Yan Wang, Thomas Liggett, et al.. (2011). Overexpression of the Dominant-Negative Form of Interferon Regulatory Factor 1 in Oligodendrocytes Protects against Experimental Autoimmune Encephalomyelitis. Journal of Neuroscience. 31(23). 8329–8341. 26 indexed citations
13.
Liggett, Thomas, Anatoliy A. Melnikov, Qilong Yi, et al.. (2010). Methylation patterns of cell-free plasma DNA in relapsing–remitting multiple sclerosis. Journal of the Neurological Sciences. 290(1-2). 16–21. 76 indexed citations
14.
Kaiser, Claudia, D. K. Shukla, Glenn T. Stebbins, et al.. (2009). A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. Journal of Neuroimmunology. 211(1-2). 124–130. 54 indexed citations
15.
16.
Loh, Yvonne, Yu Oyama, Laisvyde Statkute, et al.. (2006). Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood. 109(6). 2643–2548. 108 indexed citations
17.
Geremia, Glen, et al.. (1999). Fluoroscopically guided percutaneous needle biopsy of the cervical spinal cord.. American Journal of Roentgenology. 172(3). 723–725. 1 indexed citations
18.
Cella, David, Kelly K. Dineen, B. G. W. Arnason, et al.. (1996). Validation of the Functional Assessment of Multiple Sclerosis quality of life instrument. Neurology. 47(1). 129–139. 335 indexed citations
19.
McLeod, Bruce C., Richard J. Sassetti, Dusan Stefoski, & Floyd A. Davis. (1983). Partial plasma protein replacement in therapeutic plasma exchange. Journal of Clinical Apheresis. 1(2). 115–118. 8 indexed citations
20.
Stefoski, Dusan, Donna Bergen, Julie Fox, et al.. (1976). Correlation between diffuse EEG abnormalities and cerebral atrophy in senile dementia.. Journal of Neurology Neurosurgery & Psychiatry. 39(8). 751–755. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Philippe Truffinet Breakdown of academic impact, for papers by Vesna Brinar Breakdown of academic impact, for papers by Norman Putzki Breakdown of academic impact, for papers by Luca Massacesi Breakdown of academic impact, for papers by Mefkûre Eraksoy Breakdown of academic impact, for papers by Daniel Wynn Breakdown of academic impact, for papers by Catherine M. Dalton Breakdown of academic impact, for papers by J. A. Cohen Breakdown of academic impact, for papers by Clas Malmeström Breakdown of academic impact, for papers by Marc Debouverie
Rankless by CCL
2026